NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether NeuroPace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 27, ...

MOUNTAIN VIEW, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company has entered into a new $75 million credit facility with MidCap Financial, consisting of a $60 million term loan and a $15 million revolving credit facility. Proceeds from the new term loan were used to fully repay NeuroPace’s term loan with CRG Partners IV, L.P., with proceeds of the new revolving ...

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether NeuroPace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 27, ...

Core Viewpoint - NeuroPace, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing results from a clinical study [1][3]. Group 1: Company Performance - On May 27, 2025, NeuroPace announced the preliminary one-year results of the NAUTILUS study, which evaluated the safety and effectiveness of the RNS System for treating drug-resistant idiopathic generalized epilepsy (IGE) [3]. - The study did not achieve statistical significance for its primary effectiveness endpoint, which aimed to demonstrate a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group [3]. - Following the announcement, NeuroPace's stock price dropped by $5.02 per share, or 28.39%, closing at $12.66 per share on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of NeuroPace investors regarding possible securities fraud or other unlawful business practices by the company and its officers and/or directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information about the investigation and potential class action [1].

NeuroPace (NPCE) recently announced promising preliminary one-year results from its pivotal NAUTILUS trial, evaluating the RNS System in patients with idiopathic generalized epilepsy (IGE). This study marks a major milestone, as it is the first to assess a brain-responsive neuromodulation system in this patient population.This development positions NeuroPace as a leader in advancing neuromodulation therapies for generalized epilepsy, a segment historically underserved by current medical technologies. With t ...

NeuroPace, Inc. NPCE released preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for drug-resistant idiopathic generalized epilepsy (IGE).The study met its primary 12-week post-implant safety endpoint, demonstrating a low rate of serious adverse events related to the device and implant procedure.The study did not reach statistical significance for the primary effectiveness endpoint in the overall study population, which was to s ...

NeuroPace (NPCE) Update / Briefing May 27, 2025 08:30 AM ET Speaker0 Greetings. Welcome to the Neuropace Update Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I will now turn the conference over to Scott Schafer, Head of Investor Relations. Thank you. You may begin. Speaker1 Good morning and thank you for joining today's conference call. On the call, we will hear from Joel Becke ...

Core Insights - NeuroPace has completed the primary endpoint analysis of the one-year data from the NAUTILUS study, which is the first clinical study evaluating neuromodulation therapy for idiopathic generalized epilepsy (IGE) [1][7] - The study demonstrated excellent safety outcomes, meeting the primary safety endpoint with a low rate of serious adverse events related to the device [2][3] - While the primary effectiveness endpoint did not reach statistical significance in the overall population, a significant response was observed in a subgroup of patients with lower baseline seizure frequency [3][6] Study Results - The NAUTILUS study met its primary 12-week post-implant safety endpoint, confirming the favorable safety profile of the RNS System [2][3] - Clinically relevant data showed median percent seizure reduction and responder rates that were numerically robust and clinically meaningful over the first year of treatment [4][6] - The study included 100 participants, with 87 undergoing implantation of the RNS Neurostimulator across 23 epilepsy centers in the US [7] Future Plans - NeuroPace plans to submit the full dataset to the FDA and for peer-reviewed publication, engaging in discussions regarding regulatory pathways based on the data [8] - The company aims to expand access to RNS therapy and is confident in the potential for future indication expansion into IGE [5][8] - The company reaffirms its full-year 2025 financial guidance, indicating a strong base business growing over 20% year over year [9][5]

NeuroPace (NPCE) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Jeremy Feffer - Managing DirectorJoel Becker - CEO & Board MemberRebecca Kuhn - CFO & VP of Finance and AdministrationMike Kratky - Senior Managing Director - Medical Devices & TechnologyNelson Cox - Equity Research AssociatePriya Sachdeva - Director - Equity ResearchRohin Patel - Vice President Conference Call Participants Ross Osborn - Director, Lead Research Analyst - MedTech and DiagnosticsMike Polark - Senior Equity Re ...

NeuroPace (NPCE) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Greetings, and welcome to the NeuroPace First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce Jeremy Feffer of LifeSci Advisors. Please go ahead. Speaker1 Good afternoon. Thank you for joining us for Neuropace's first quarte ...